NDAORALTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal…
Pharmacologic Class:
Central Nervous System Stimulant
Clinical Trials (1)
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
Started May 2019
Loss of Exclusivity
LOE Date
Jun 28, 2032
76 months away
Patent Expiry
Jun 28, 2032